N., Wharton, S., Connery, L., Alves, B., & Kushner, R
In June 2025, MBX Biosciences In announced it received preliminary feedback from the FDA on its planned Type B pre-IND meeting, supporting the advancement of its EL-22 program in combination with GLP-1 receptor agonists toward a Phase 2 clinical trial
Inhibiting glucagon secretion : It puts the brakes on your livers glucose production, further contributing to improved blood sugar control
However, kidney and heart protection are not fully explainable by the metabolic actions of these agents
8
Use these red flags as a quick filter before you buy anything in this category: Brand name drug language, like Ozempic or semaglutide, with no prescription required Claims of being clinically proven with no study, dose, or testing details attached No clear ingredient amounts or transparent third party testing information Dramatic promises anchored to before and after photos rather than data Marketing that looks like a medical treatment but sells as a cosmetic supplement This is exactly where a responsible medical aesthetics clinic steps in